DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
This study tests a new drug called DZD8586 in patients whose B-cell non-Hodgkin lymphoma has returned or stopped responding to previous treatments. The main goals are to find out what side effects the drug causes and measure how much of it stays in the body over time.
Key Objective: This trial investigates whether DZD8586 can help control B-cell non-Hodgkin lymphoma in patients who have not benefited from other available treatments.
Who to Consider: Patients with relapsed or refractory B-cell non-Hodgkin lymphoma who have failed or cannot tolerate standard systemic therapy should consider enrolling.
Trial Parameters
Brief Summary
This study will treat patients with B-NHL who have relapsed, progressed, or were intolerant to systemic therapy progressed following prior therapy. This study will help to understand what type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and assess its anti-cancer activity as monotherapy.
Eligibility Criteria
Inclusion Criteria: 1. Male or female participants who have provided ICF with age ≥ 18 yrs 2. ECOG performance 0-2, no deterioration in the past 2 weeks 3. Participants with relapsed or refractory B-NHL must have cytologically or histologically confirmed B-cell lymphoma 4. Adequate bone marrow reserve and organ system functions 5. Participants willing to comply with contraceptive restrictions Exclusion Criteria: 1. Any unresolved \> Grade 1 adverse event at the time of starting study treatment with the exception of alopecia. 2. Prior history of allogeneic hematopoietic stem cell transplantation 3. Stem cell transplantation, cell therapy, or gene therapy within 90 days. Approved small molecule therapy within 5 half-lives, investigational small molecule therapy within 14 days. Monoclonal antibodies and antibody-drug conjugates within 28 days Radiation therapy within 1 weeks 4. Live attenuated vaccines or viral vector vaccines within 4 weeks. Major surgery or significant traumatic injury